Skip to main content
Fig. 4 | Arthritis Research & Therapy

Fig. 4

From: Non-invasive monitoring of arthritis treatment response via targeting of tyrosine-phosphorylated annexin A2 in chondrocytes

Fig. 4

Monitoring arthritis disease remission using LS301. A Representative fluorescence images of arthritic mice imaged with LS301 at disease day 4 (left) and after disease remission (right). C57BL/6 mice (n = 3 per group) with induced arthritis (STA) were imaged with 6 nmol intravenous LS301 at day 4 post disease induction. At day 23 post-disease induction when the clinical paw scores of mice were near baseline, mice were imaged again with 6 nmol intravenous LS301. Whole body near-infrared fluorescence images were taken on the Pearl animal imaging system with λ = 820 nm. Images were taken at 18h post-injection with mice in dorsal orientation and depict representative independent replicates. Numbers denote individual clinical paw scores at the time of imaging. B Comparison of average total extremity fluorescence (quantitated from ROIs) per mouse described in A. C Total paw arthritis scores and change in ankle thickness from baseline of mice described in A

Back to article page